| Literature DB >> 20870461 |
Helena Slaets1, Jerome J A Hendriks, Piet Stinissen, Trevor J Kilpatrick, Niels Hellings.
Abstract
Therapies for multiple sclerosis (MS) reduce the relapse rate but are unable to stop neurological decline. Here, we evaluate the potential of leukemia inhibitory factor (LIF) as a novel therapeutic in diseases with a neurodegenerative and inflammatory component, such as MS. LIF, which can be a proinflammatory cytokine, can also modulate the immune response in a beneficial way. Recent evidence demonstrates a crucial role of LIF in neuroprotection and axonal regeneration as well as the prevention of demyelination. Finally, LIF is an important survival factor for stem cells and neuronal precursors. Therefore, we propose that LIF is a potential therapeutic candidate for MS.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20870461 DOI： 10.1016/j.molmed.2010.08.007
Source DB: PubMed Journal: Trends Mol Med ISSN： 1471-4914 Impact factor: 11.951